Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 8/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730377 | 1.00 | MAPT (0.38) | MAPTTDP1SMN1; SMN2MEN1GAA | |
| SCHEMBL23797497 | 0.88 | MAPT (0.38) | MAPTTDP1SMN1; SMN2MEN1GAA | |
| SCHEMBL23797245 | 0.85 | MAPT (0.39) | MAPTTDP1SMN1; SMN2MEN1GAA | |
| SCHEMBL8836642 | 0.85 | TDP1 (0.42) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL1729943 | 0.84 | MAPT (0.39) | MAPTSMN1; SMN2MEN1GAAKMT2A | |
| SCHEMBL6062712 | 0.84 | MAPT (0.39) | MAPTSMN1; SMN2MEN1GAAKMT2A | |
| SCHEMBL5147739 | 0.80 | CTSK (0.39) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL1728426 | 0.79 | MAPT (0.34) | MAPTSMN1; SMN2 | |
| SCHEMBL4399131 | 0.79 | ALDH1A1 (0.47) | MAPTCTSKCTSSCTSLCTSB | |
| SCHEMBL6062681 | 0.79 | MAPT (0.34) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008957-B2 | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | MAPT 4510/4885TDP1 4138/4885SMN1; SMN2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.